When does guidance say a specialist is warranted?
Two triggers are written down rather than left to a feeling. NICE names two severe forms for same-day specialist assessment. The International Psoriasis Council sets out who counts as a candidate for systemic therapy, which is care a dermatologist directs. Evidence Evidence
How to use this step
- Reasonably supported
I read NICE first. It records same-day specialist assessment for generalised pustular psoriasis or erythroderma. The International Psoriasis Council dropped the mild, moderate and severe scale. In its place a person is a candidate for topical therapy, or a candidate for systemic therapy. Any one of three criteria puts a person in the systemic group. The first is psoriasis on 10% or more of the body surface. The second is psoriasis on a high-impact site. The council names the face, palms, soles, genitalia, scalp and nails. The third is failure of topical therapy.
Check before moving on
- Depends on you
What that means for you is that a referral rests on written criteria, not on how bad a week felt. I compared the two, and they answer different halves of the question. NICE is UK guidance and names no US referral route. The council statement is a professional consensus. Neither one decides your case.
Questions for the clinic or clinician
Based on where and how much of my skin is affected, do I meet the criteria for systemic therapy?
Saving keeps this on your device and needs JavaScript, which is off in this browser.What would you put in a referral letter for me?
Saving keeps this on your device and needs JavaScript, which is off in this browser.
Which directory do you start with?
Start with the American Academy of Dermatology public search, your health plan network list, and a referral from a clinician you already trust. A listing is a place to start, not a ranking. Evidence
How to use this step
- Reasonably supported
The Academy runs a public Find a Dermatologist search, and its patient pages point to it. I looked at what that search can actually do. It lists Academy members, so inclusion reflects membership and board certification. It cannot be filtered by condition. A listing establishes that a name is in a directory, and nothing else.
Check before moving on
- Depends on you
What that means for you is that no directory shows who treats psoriasis often. I looked for one and did not find it. A listing shows no availability and no quality of care. Directory and network records also go out of date, so the phone call does the work the listing cannot.
Questions for the clinic or clinician
Is this dermatologist board-certified, and where can I check that?
Saving keeps this on your device and needs JavaScript, which is off in this browser.How recently was this listing confirmed with the office?
Saving keeps this on your device and needs JavaScript, which is off in this browser.
What do you ask the office before you book?
Ask what the practice itself provides. Three services carry most of the weight in psoriasis: light treatment, biologic medicines, and joint care shared with rheumatology. A practice that does not run one of them should still say where it refers. Evidence Evidence Evidence
How to use this step
- Reasonably supported
Whether a biologic will clear you, and what side effects come with it, is one of the questions psoriasis readers ask most. I read the American Academy of Dermatology on the three services. It records narrowband UVB as light treatment a dermatologist sets and adjusts, with response evaluated after the first several treatments. It records that a biologic quiets the part of the immune system that psoriasis has made overactive. Blood tests and tuberculosis testing are typically required before starting one. It records that biologics can stop psoriatic arthritis joint pain, stiffness and swelling. The joint AAD and NPF comorbidity guideline asks clinicians to screen people with psoriasis for psoriatic arthritis.
Check before moving on
- Depends on you
What that means for you is that a practice can suit you without offering every service. These records describe the services, not the practices. I could not find an office near you, a waiting time, or a referral route named in any of them.
Questions to ask when you phone the office
Does this practice run narrowband UVB on site, or refer out for it?
Saving keeps this on your device and needs JavaScript, which is off in this browser.Does the clinician prescribe biologics, and who arranges the tests first?
Saving keeps this on your device and needs JavaScript, which is off in this browser.If my joints are involved, do you work with rheumatology on that?
Saving keeps this on your device and needs JavaScript, which is off in this browser.
What does your plan change about the shortlist?
Two plan rules move the shortlist more than any directory does. The first is whether the office is in network. The second is step therapy, where a plan asks you to try a cheaper medicine first. Evidence
How to use this step
- Reasonably supported
The 2019 National Psoriasis Foundation patient survey I read found that 41% of people with psoriatic disease had gone through step therapy. By the Foundation’s own count, more than 25 states have passed a step-therapy law. That law gives a patient a way to ask for an exception. The Foundation wants that same process in every state.
Check before moving on
- Depends on you
What that means for you is that this is worth raising before you book, not after. The survey counted people, not health plans. I checked who stands behind it: the Foundation lobbies against step therapy and lists drug makers among its members. Your own plan document sets your rule.
Questions for the clinic or clinician
Is this office in network for my plan this year?
Saving keeps this on your device and needs JavaScript, which is off in this browser.Who in the office files a step-therapy exception?
Saving keeps this on your device and needs JavaScript, which is off in this browser.
What if the first free appointment is months away?
A wait is easier to carry with a dated written assessment behind it. Ask the doctor you can see now to assess and record. NICE describes one psoriasis assessment, and its treatment map holds topical options as well as light and systemic ones. Evidence
How to use this step
- Reasonably supported
NICE sets out one psoriasis assessment, and I went through what it holds. It covers the skin, the nails and high-impact sites. It covers the impact on daily life. It covers joint concerns. Its treatment map holds topical options alongside light and systemic ones.
Check before moving on
- Depends on you
What that means for you is that an assessment written down today travels with you to the specialist. NICE is UK guidance. It sets no waiting time, creates no US treatment order, and decides urgency for nobody.
Questions for the clinic or clinician
Can you write my assessment down today, so the referral carries it?
Saving keeps this on your device and needs JavaScript, which is off in this browser.Which part of the treatment map can start before I am seen?
Saving keeps this on your device and needs JavaScript, which is off in this browser.
What if the fit is wrong once you are there?
Asking another qualified clinician is a normal step, not a complaint. What makes the second visit useful is the record you carry into it: dates, what was tried, and what changed. Evidence
How to use this step
- Reasonably supported
I read the National Psoriasis Foundation on preparing for a visit. It records bringing a symptom tracker to an appointment. It can be kept on paper or on a phone, and shared with the doctor. The Foundation records describing symptoms clearly. It records noting changes in severity and in the areas affected as part of preparing for a visit.
Check before moving on
- Depends on you
What that means for you is that the record is the part you control. I rate no clinician against another here. I set no review date and name no second-opinion route, so the timing stays a conversation.
Questions for the clinic or clinician
What question do I most need a second opinion to answer?
Saving keeps this on your device and needs JavaScript, which is off in this browser.Which records and photos should I bring to a new clinician?
Saving keeps this on your device and needs JavaScript, which is off in this browser.
Evidence behind this page
Sources
Each evidence badge opens the source and its limits. The full list stays available here.
- American Academy of DermatologyPatient education · Patient education, tier 5Relevant relationship disclosed
- Published
- SteadySkin last checked
What this source can and cannot tell you
Why the independence label says this: The Academy lists its own members. Inclusion reflects membership and board certification, not an assessment by anyone outside the organization.
What this source supports
Supports searching for board-certified dermatologists by location. It is the tool the AAD patient pages point to, and it is the starting point the site has always described in words.
What it does not support
A directory listing is not evidence about a clinician. It does not establish relevant experience, current availability, quality of care, or that the listing is up to date, and none of these tools can be filtered by condition.
Claim-specific review for this source is still in progress. Only the source-level evidence and limits are shown here.
- National Psoriasis FoundationPatient education · Patient education, tier 5Relevant relationship disclosed
- Published
- SteadySkin last checked
What this source can and cannot tell you
Why the independence label says this: The National Psoriasis Foundation names its corporate members on its own site (psoriasis.org/corporate-members/, checked 2026-09-09). They include AbbVie, Johnson & Johnson, Leo Pharma, Lilly, Novartis, UCB, Amgen, Sun Pharma, Arcutis, Bristol Myers Squibb, Takeda, and Alumis. Several of those firms make the drugs step therapy and copay-card rules affect. NPF also lobbies against both practices. This number and its framing come from a group with a stake in the fight, even though NPF says it does not back one drug over another.
What this source supports
Supports that a 2019 NPF patient survey found 41% of people with psoriatic disease had gone through step therapy. Supports that, by NPF's own count, more than 25 states have passed a step-therapy law. That law gives a patient a way to ask for an exception. Also supports that NPF wants that same process in every state.
What it does not support
Does not give the survey's size or its margin of error. Does not say which state laws name psoriasis drugs by name. Does not say if a given plan falls under state law at all; a plan an employer funds itself usually does not. The page shows no post or update date. The date used here is the newest state law it names: a Wisconsin law from July 2020. The page itself may be newer. The state count may be out of date too. Does not guess what any one plan will require.
Claim-specific review for this source is still in progress. Only the source-level evidence and limits are shown here.
- International Psoriasis CouncilGuideline · Clinical research, tier 2Relevant relationship disclosed
- Published
- SteadySkin last checked
What this source can and cannot tell you
Why the independence label says this: The International Psoriasis Council names its corporate members on its own site (psoriasiscouncil.org/about/corporate-members/, checked 2026-09-11). The top tier names AbbVie, Johnson & Johnson, Eli Lilly, Novartis and Takeda. LEO Pharma, UCB, Almirall, Sun Pharma, Amgen, Alumis, Arcutis and Oruka sit below them. Those firms make the drugs this severity rule opens the door to. A wider rule on who qualifies is a wider market for them. The page says nothing about how that money relates to IPC independence.
What this source supports
Supports that IPC dropped the mild, moderate and severe scale. In its place a person is a candidate for topical therapy, or a candidate for systemic therapy. Supports that any one of three criteria is enough to be a candidate for systemic therapy. The first is psoriasis on 10% or more of the body surface. The second is psoriasis on a high-impact site. IPC names those sites as the face, palms, soles, genitalia, scalp and nails. The third is failure of topical therapy. Supports that IPC defines that failure in writing. It is not reaching clear or almost-clear skin after two four-week courses in a row. IPC gives clear or almost-clear as 1% or less body surface, with a physician global assessment of 0 or 1. Supports the source paper. It is Strober B, Ryan C, van de Kerkhof P, et al. Recategorization of psoriasis severity: Delphi consensus from the International Psoriasis Council. J Am Acad Dermatol 2020 Jan;82(1):117-122. Supports that IPC's own June 2025 teaching deck lists payers among the groups it set out to move. That deck also names refusal to pay as a result of the older scale.
What it does not support
Does not set any health plan's coverage rule. This is a professional-society consensus. It is not a regulation and not a plan document. Does not say which systemic treatment follows once a person meets a criterion. It sets no dose, no frequency and no schedule. Does not give the number of experts who voted, the response rate, or their conflict-of-interest disclosures. IPC's own June 2025 deck states the body-surface threshold two ways. Its criteria summary says 10% or more. The slide expanding that criterion says above 10%. Does not establish that a given reader meets a criterion. It predicts nothing about what a plan will decide.
Claim-specific review for this source is still in progress. Only the source-level evidence and limits are shown here.
- Journal of the American Academy of Dermatology (Elmets CA, Leonardi CL, Davis DMR, et al.)Guideline · Regulatory / guideline, tier 1Relevant relationship disclosed
- Published
- SteadySkin last checked
What this source can and cannot tell you
Why the independence label says this: The guideline reports author relationships with industry. It is expert guidance, not independent proof for one person.
What this source supports
Supports that this guideline covers psoriasis alongside other health conditions. Supports naming psoriatic arthritis as one of them. Supports naming heart and blood vessel disease. Supports naming obesity, high blood pressure, raised blood fats and diabetes. Supports naming inflammatory bowel disease. Supports naming uveitis, an inflammation inside the eye. Supports naming depression and anxiety. Supports that it asks clinicians to screen people with psoriasis for psoriatic arthritis. Supports that it asks them to check heart risk factors. Supports naming body weight, blood pressure, blood fats and blood sugar among those checks. Supports that it asks them to screen for depression.
What it does not support
Does not diagnose a reader. Does not say which linked condition one person will get. Does not read a test result or set a personal plan. Its authors report industry relationships. It is US guidance. It does not set practice in another country.
Claim-specific review for this source is still in progress. Only the source-level evidence and limits are shown here.
- National Psoriasis FoundationPatient education · Patient education, tier 5Independent source
- Published
- SteadySkin last checked
What this source can and cannot tell you
What this source supports
Supports bringing a symptom tracker, kept on paper or on a phone, to share with a doctor at an appointment. Supports clearly describing symptoms and noting changes in severity and affected areas as part of preparing for a visit.
What it does not support
Does not mention photographing skin changes specifically. The page shows no visible byline or update date. The site copyright year, 2026, is used here.
Claim-specific review for this source is still in progress. Only the source-level evidence and limits are shown here.
- National Institute for Health and Care ExcellenceGuideline · Regulatory / guideline, tier 1Independent source
- Published
- SteadySkin last checked
What this source can and cannot tell you
What this source supports
Supports psoriasis assessment across skin, nails, high-impact sites, life impact and joint concerns; same-day specialist assessment for generalised pustular psoriasis or erythroderma; and a treatment map that includes topical, phototherapy and systemic options.
What it does not support
It is UK guidance and does not diagnose a reader, create a US treatment sequence, determine personal urgency from a description, or establish current US labeling or coverage.
Claim-specific review for this source is still in progress. Only the source-level evidence and limits are shown here.
- American Academy of DermatologyPatient education · Patient education, tier 5Independent source
- Published
- SteadySkin last checked
What this source can and cannot tell you
What this source supports
Supports that narrowband UVB works by slowing the growth of rapidly growing skin cells and suppressing an overly active immune system. Supports that it also reduces inflammation and reduces or eliminates itch. Supports that most patients need regular sessions across several weeks, on a schedule the dermatologist sets and adjusts, and that steady improvement follows a consistent schedule. Supports that dermatologists typically evaluate response after the first several treatments. Supports the immediate side effects: a sunburn-like reaction, mild stinging or burning, dark spots more common in medium-to-dark complexions, itching, and rare blisters or burns. Supports the long-term effects: freckles, early skin aging, and increased skin cancer risk. Supports that the treatment is considered safe and effective for most people with psoriasis, including children, pregnant women, and people who are immunocompromised, without stating an exact success percentage.
What it does not support
Does not state a specific response percentage, does not quantify the rate of any individual side effect, and does not give a retail price or insurance-coverage detail.
Claim-specific review for this source is still in progress. Only the source-level evidence and limits are shown here.
- American Academy of DermatologyPatient education · Patient education, tier 5Independent source
- Published
- SteadySkin last checked
What this source can and cannot tell you
What this source supports
Supports that a biologic specifically targets, or quiets, the part of the immune system that is overactive because of psoriasis. Supports the twelve named FDA-approved biologics (Cimzia/certolizumab pegol, Cosentyx/secukinumab, Enbrel/etanercept, Humira/adalimumab, Ilumya/tildrakizumab, Remicade/infliximab, Siliq/brodalumab, Simponi/golimumab, Skyrizi/risankizumab, Stelara/ustekinumab, Taltz/ixekizumab, Tremfya/guselkumab). Supports that dosing is given as a shot or an infusion, with dosing frequency ranging from twice a week to once every three months. Supports that infliximab specifically requires an in-office or infusion-center IV infusion rather than a self-administered shot. Supports that biologics can stop psoriatic-arthritis joint pain, stiffness, and swelling and prevent it from worsening. Supports the common side effects of upper respiratory tract infection, injection-site skin reaction, flu-like symptoms, urinary tract infection, and headache. Supports that biologics raise infection risk, particularly for people with diabetes, tobacco use, an infection history, or advanced age. Supports that blood tests and tuberculosis testing are typically required before starting, with some patients needing additional tests. Supports that four biologics are FDA-approved for children with moderate-to-severe psoriasis from around age four to six and up, depending on the drug.
What it does not support
Does not report PASI or other trial-response data, a boxed-warning quote for any specific drug, an exact screening protocol, or cost/pricing information. Does not predict an individual reader’s response or risk.
Claim-specific review for this source is still in progress. Only the source-level evidence and limits are shown here.